Edwards to market PLC's TMR heart laser in US:
This article was originally published in Clinica
Executive Summary
Edwards Lifesciences is to have exclusive rights to sell PLC Medical Systems' next generation CO2 TMR heart laser in the US under a multi-year agreement. The product is awaiting FDA approval. Edwards will also take a $4 million equity investment in Franklin, Massachusetts-based PLC and will receive warrants to buy three million shares. "We believe Edwards' substantial sales and marketing resources combined with PLC's technological leadership will establish CO2 TMR as the standard of care in laser-powered heart revascularisation," said Mark Tauscher, PLC's CEO.